The Unapproved Drugs Development Support Center (a tentative name for the new organization), which will support domestic research, development and production of medicines that have not been approved for use in Japan financially and technically, has now been formally established in order to eliminate the so-called, "drug-lag," the Japan Pharmaceutical Manufacturers Association announced. A project team to act on this issue was convened earlier this year (Marketletter January 26).
The set up consists of 69 JPMA member companies. Fumimaro Takaku, president of the Japanese Association of Medical Sciences and also of the Jichi Medical School, has been appointed to the role of president of the new Center. It has said that the JPMA is aiming to demonstrate the manufacturers' efforts to eliminate the drug-lag as the producer-side an attempt to introduce a new National Health Insurance drug pricing system, or a drug price maintenance exception system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze